Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Sorrento Therapeutics Inc SRNE

Healthcare Biotechnology
Sorrento Therapeutics, Inc. is a clinical and commercial stage biopharmaceutical company. The Company is engaged in developing new therapies to treat cancer, pain (non-opioid treatments), autoimmune diseases and COVID-19. The Company’s segments include Sorrento Therapeutics and Scilex. The Sorrento Therapeutics segment is organized around its Immune-Oncology therapeutic area, leveraging its G... see more

Recent & Breaking News (GREY:SRNE)

Sorrento Announces Positive Data from a Combined Phase 2 & 3 Clinical Study of STI-004, an Anti-IgE Biosimilar Antibody

PR Newswire May 16, 2016

Sorrento Therapeutics engaged advisors for exploring strategic alternatives

PR Newswire May 9, 2016

Wildcat Capital Issues Letter to Board of Sorrento Therapeutics

PR Newswire May 6, 2016

Sorrento closes private placement with Yuhan Corporation

PR Newswire May 2, 2016

Sorrento to Present at 2 Upcoming Conferences in New York City

PR Newswire May 2, 2016

Sorrento to Present at the Upcoming American Association for Cancer Research (AACR) Annual Meeting

PR Newswire April 14, 2016

Sorrento to Present at the Jefferies Immuno-Oncology Summit

PR Newswire April 6, 2016

Sorrento Appoints Kevin M. Herde As Chief Financial Officer

PR Newswire April 5, 2016

Sorrento Announces Definitive Agreements for up to $150 Million Private Placement

PR Newswire April 4, 2016

Sorrento to Present at the 28th Annual ROTH Conference

PR Newswire March 14, 2016

Sorrento to Present at the Cowen and Company 36th Annual Health Care Conference

PR Newswire March 4, 2016

Yuhan Corporation And Sorrento Therapeutics Form Joint Venture Company - ImmuneOncia

PR Newswire March 2, 2016

Sorrento Therapeutics Reports 6.92% Passive Stake in NantKwest in 13G

Press Releases February 17, 2016

OncBioMune Patents a New Promising Approach to Chemotherapy

Accesswire January 28, 2016

Sorrento Announces Positive Data from Phase 3 studies of Biosimilar Antibodies, STI-001 and STI-002

PR Newswire January 11, 2016

Sorrento and Karolinska Institutet Establish Exclusive Partnership for Research and Development of Natural Killer Cell-based Therapies

PR Newswire January 11, 2016

Immunotherapy Inside the Cell Interview by The Life Sciences Report

Marketwired January 8, 2016

Upcoming Corporate Presentations In San Francisco

PR Newswire January 8, 2016

Perception, Opportunity in Volatility - Analyst Research on Workiva, Sorrento Therapeutics, Coeur Mining and Kraton Performance Polymers

Accesswire December 14, 2015

Sorrento Expands its Executive Management Team with Appointment of Dr. Jeffrey Su as Chief Operating Officer to Lead its in-house Bioprocess and Manufacturing Operations

PR Newswire October 19, 2015